Clinical Study
The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer
Table 1
Baseline characteristics of all patients, including collected prevalence of osteoporosis risk factors.
| | Age () (Standard Deviation) | 73.3 years (7.4) | | Years between diagnosis and study entry () | 4.3 years (0.2) | | Number of ADT injections received () | 8.9 (6.1) | | PSA at first visit () | 22.4 (61.5) | | Gleason score () | 7.6 (1.0) | | Height () | 170.7 cm (21.2) | | Weight () | 88.2 kg (17.4) | | Prostate cancer stage 1A, 1B, or 1C | 24.6% (35/142) | | Prostate cancer stage 2A, 2B, or 2C | 44.4% (63/142) | | Prostate cancer stage 3A, 3B, or 3C | 31.0% (44/142) | | Prior hip fracture before treatment | 0% (0/147) | | Prior vertebral fracture before treatment | 1.4% (2/148) | | Prior fracture before treatment (excluding hip or vertebral) | 1.4% (2/148) | | History of smoking | 50.3% (74/147) | | Current smoker at first visit | 17% (25/147) | | Steroid use during followup | 3.3% (5/150) | | SSRI use during followup | 10.7% (16/150) | | Anticonvulsant use during followup | 4.7% (7/150) | | HRT use during followup | 13.5% (20/148) |
|
|
